Resolvyx enters deal with NNRI for resolvin

The USA's Resolvyx Pharmaceuticals, a Bedford, Massachusetts-headquartered, privately-held biopharmaceutical company, has entered an agreement with the National Neurovision Research Institute to explore novel resolvin therapeutics for eye diseases of the retina that lack current treatments, specifically genetic retinal degenerative diseases and dry age-related macular degeneration.

Under the accord, the NNRI, a recently-established non-profit support organization of the Foundation Fighting Blindness, will fully fund preclinical studies and provide access to specialized research facilities and ocular research experts to evaluate the effectiveness of the new class of drugs, including RX-10001, RX-10008, and RX-20001. Resolvyx will retain all rights to develop and commercialize these compounds and any discoveries that result from the collaboration.

"We are extremely encouraged by the potential for resolvins to treat a number of serious eye diseases, as we have demonstrated that resolvins have a unique ability to naturally inhibit key inflammatory processes, preserve the integrity of eye tissue and promote eye tissue repair," said Per Gjorstrup, chief medical officer of Resolvyx.